Low efficiency of leucocyte plugging-based drug delivery to cancer in mice

Drug Deliv Transl Res. 2022 Jun;12(6):1475-1487. doi: 10.1007/s13346-021-01028-y. Epub 2021 Jul 28.

Abstract

Cells of the immune system were proposed for use as Trojan horse for tumour-specific drug delivery. The efficacy of such cell-based drug delivery depends on the site-specific cell homing. This present study was aimed to investigate the potential of leucocytes for intratumoural site-specific enrichment using a locoregional application route in experimental liver tumours. Human neutrophils were isolated from peripheral blood and directly labelled with calcein AM or loaded with doxorubicin. The neutrophil loading and release of doxorubicin and the migration and adhesion to ICAM-1 were analysed in vitro. Macrophages were isolated and activated in vitro. Leucocyte plugging and the distribution pattern in the liver microvasculature were studied ex vivo, and the efficacy of leucocyte plugging in tumour blood vessels was analysed in vivo after superselective intra-arterial injection in mouse liver tumour models. Neutrophils were characterised by the high dose-dependent uptake and rapid release of doxorubicin. Doxorubicin loading did not affect neutrophil migration function. Neutrophil plugging in liver microvasculature was very high (> 90%), both after ex vivo perfusion and after injection in vivo. However, neutrophils as well as activated macrophages plugged insufficiently in tumour blood vessels and passed through the tumour microvasculture with a very low sequestration rate in vivo. Neutrophils possess several properties to function as potentially effective drug carriers; however, the tumour site-specific drug delivery after selective locoregional injection was observed to be insufficient owing to low intratumoural microvascular plugging.

Keywords: Leucocyte plugging; Liver tumour; Mouse model; Trojan horse.

MeSH terms

  • Animals
  • Doxorubicin
  • Drug Carriers
  • Drug Delivery Systems*
  • Liver Neoplasms* / drug therapy
  • Mice

Substances

  • Drug Carriers
  • Doxorubicin

Grants and funding